Global pharma giant Eli Lilly plans to launch its diabetes and obesity treatment, tirzepatide, marketed under the brands ...

Leerink Partners analyst Mike Kratky has maintained their neutral stance on INSP stock, giving a Hold rating on December 9.Don't Miss Our ...

The first medication for obstructive sleep apnea has been approved by the US Food and Drug Administration (FDA).

The US Food and Drug Administration has approved Zepbound (tirzepatide) as the first prescription medication for the treatment of obstructive sleep apnea (OSA).

For a long time, dieting and exercise were the only realistic options for many people who wanted to lose weight, but recent ...

The Food and Drug Administration (FDA) announced the approval of the weight loss drug Zepbound, generically known as ...

Innovation, artificial intelligence, drug costs and shortages, private equity interests, and more left their mark in ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

Coming off of Novo Nordisk's (NVO) sharp stock decline after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted, BMO Capital Markets ...

Recent pharmaceutical innovations have opened a new path for weight loss through drugs based on gut hormones such as GLP-1 ...

The FDA approves Zepbound, originally used for type 2 diabetes and weight loss, for treating obstructive sleep apnea (OSA) in ...